Abstract: A solid pharmaceutical composition for oral administration comprising a cyclosporin and an anionic surfactant, preferably sodium lauryl sulfate, wherein the amount of anionic surfactant is at least about forty percent of the minimum amount needed to dissolve the cyclosporin in water.

Abstract: A skylight is disclosed for installation in an opening disposed in the top of an enclosure. The skylight includes framing sections providing for variation in installations and accommodating on site adjustments when fastening and fitting the skylight within the opening of the enclosure. The framing sections are adapted to receive supplementary moldings adapted to friction fit with the framing section which provide for variation in installation tolerances and cover any undesirably exposed portions of the enclosure resulting from installation of the skylight, while accommodating on site adjustments.

Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

Abstract: A standardized block for forming a retaining wall, said block comprising a top and bottom and having disposed proximate the top thereof first, second and third abutment means, and having disposed proximate the bottom thereof fourth, fifth and sixth abutment means, said second and fifth abutment means abutting in a first abutting position when like blocks are placed course upon course to form a retaining wall having a substantially vertical alignment, said first abutment, said second abutment and said third abutment abutting with said fourth, fifth and sixth abutment in a second abutting position different from said first position when like blocks are placed one upon the other, course upon course, to provide a substantially set-back retaining wall construction, and wherein said first, second and third abutment means abut with said fourth, fifth and sixth abutment means in a third abutting position different from said second or first position when like blocks are placed one upon another, course upon course, to

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue or a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units or hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue or a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A standard sized, or standard shaped profile for use as header, sill, latch jamb and/or striker jamb portions within a framing section, each of the standard shaped and sized profiles includes a first side and a second side wherein are provided mounting portions to mount the framing sections via a supplementary member engaged with the mounting portions to a wall adjacent an opening and thereby enable a wing pivoted from said completed frame to be swung inwardly in a first embodiment or outwardly in a second embodiment from framing sections made from the identical profiles.

Abstract: The invention relates to a method of rapidly transporting a drug to the epidermis and accumulating and maintaining the drug therein for a prolonged period of time comprising administration of a therapeutically efective non-toxic amount of the drug with an effective amount of hyaluronic acid.

Abstract: A method of treating a disease or condition comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: A process is provided for the preparation of 1,2,5,6-tetrahydro-3-carboalkoxypyridines of formula (III) ##STR1## wherein R is a straight or cyclic substituted or unsubstituted alkyl chain having 1 to 6 carbon atoms, phenyl C.sub.1-6 alkyl, menthol or a derivative of menthol, or a derivative of camphor, and R' is an alkyl chain having 1 to 4 carbon atoms or phenyl C.sub.1-6 alkyl comprising reacting an alkyl pyridinium salt of formula ##STR2## wherein R and R' are as defined above and X is a suitable leaving group with sodium triacetoxyborohydride in the presence of an acid.

Abstract: A valve assembly is provided including a housing having an opening wherein a cartridge is inserted. The housing has axially aligned inlets and outlets for hot and cold water. The cartridge includes a stationary sleeve containing a rotatable stem member. The stem member carries a compound seal having a first primary sealing portion for sealing the inlet of the stationary sleeve and a secondary seal portion for separating first and second chamber areas of the stem member. Preferably the outlets of said moveable stem and said stationary sleeve are substantially L-shaped, and inverted L-shaped respectively, which are selectively alignable to provide for an increased volume of water through the valve assembly. The housing includes a dividing dam in the outlet splitting the outlet in two.

Abstract: A process is provided for the preparation of compounds of formula I, ##STR1## useful in the preparation of compounds such as Omeprazole, Lansoprazole and Pantoprazole, wherein R.sup.1 =H or CH.sub.3, R.sup.2 =H or CH.sub.3, R.sup.3 =Alkoxy (1-4C), OCH.sub.2 CF.sub.3, Cyano, Hydrogen, Halogen, Acetoxy or Aryloxy, any electron withdrawing group or salts (organic or inorganic) of electron donating groups, R=Alkoxy, Hydroxy, Halogen, Activated ester, Tosylate, Mesylate, Thiol or Xanthyl, wherein the process for the preparation of compound of formula I employs a free radical reaction to functionalize the 2-position.

Abstract: A loading dock bumper comprising:(a) a first rigid part for fastening to said dock(b) a second rigid part engaged with said first rigid part by at least one connecting device, said second rigid part being moveable with respect to said first rigid part between a first and a second position, and said first and said second rigid parts when engaged defining a substantially enclosed hollow therebetween; and(c) a compressible resilient material dispersed between said first and second rigid parts within the hollow therebetween,wherein said second part is moveable with respect to the first part between the first position wherein the resilient material is not compressed and the second position wherein said resilient material is compressed, wherein any load applied to said bumper moves the second part towards the second position and compresses the resilient material to provide dampening of the load applied.

Abstract: A cartridge for a valve housing having outlets, the cartridge comprising a stationary body sleeve for fixed insertion within the housing and having outlet ports permanently aligned with the outlets of the housing, a moveable substantially hollow stem sleeve inserted within the stationary body sleeve and having an opening selectively alignable with the ports of the stationary body sleeve, the body sleeve and hollow stem being connected to one another by a retaining ring which aligns and maintains the cartridge as a unit in the housing. The diverting valve may be installed as a deck mounted fixture in a tub, whirlpool, soaking bath, spa, roman tub, or the like wherein the tub spout is located below the flood line rim of the respective fixture wherein the diverting valve can be repaired by replacing the cartridge from the top of the valve by removing the handle and replacing the cartridge in its entirety.

Abstract: A process is provided for the manufacture of 4-lower-alkyl-5-hydroxymethyl-imidazole comprising reacting (4)-lower-alkyl imidazole with formaldehyde in an alkanol solvent having from 2 to 5 carbon atoms in the presence of a solid mild base suspended in the solvent.

Abstract: A method of accumulating a drug and a form of hyaluronic acid in the skin and/or exposed tissue of a human includes topically administering a therapeutically effective dosage amount of a formulation which comprises at least 5 mg/cm.sup.2 of the form of hyaluronic acid and a therapeutically effective amount of the drug.

Abstract: A winch assembly is provided including a single mounting bracket for mounting the winch assembly directly to a frame (for example beams) of a vehicle having a front and rear. The mounting bracket has a winch mounting area provided therewith, and a tire carrier and cooperative flexible member outlet area spaced from the winch mounting area towards the front of the vehicle. The mounting bracket is adapted to bolt directly to the frame members (for example beams) of a vehicle. The mounting bracket for the winch therefore obviates the need to provide welded or fastened reinforcing plates with the vehicle proximate the locations wherein the winch assembly is to be mounted.

Abstract: Pharmaceutical compositions from which effective non-toxic (to the patient) dosage amounts may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat and to assist to resolve a disease and/or condition of the skin and/or exposed tissue of a human and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to transport (to facilitate or cause the transport of) the drug, to a site in the skin including epidermis or exposed tissue of a disease or condition for percutaneous transport into the skin and/or exposed tissue to accumulate and remain there for a prolonged period of time and which is systemic independent acting.

Abstract: A peritoneal dialysis solution consisting essentially of an effective amount of N-acetylglucosamine and electrolytes.

Abstract: Novel methods for the synthesis of substituted ureas and guanidines including Terazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin, Quinasin and Bunazosin (exemplary of 2-amino substituted Quinazolines), Meobentine and Bethanidine and novel intermediates suitable for use in such methods of synthesis are taught.

Abstract: A pharmaceutical composition is provided comprising:(1) an agent selected from a medicinal agent and a therapeutic agent and combinations thereof in a therapeutically effective amount to treat a disease or condition in humans who will benefit from the treatment with the agent; and(2) hyaluronic acid and/or pharmaceutically acceptable salts thereof and/or fragments, and subunits of hyaluronic acid, characterized in that said composition(a) is in a dosage form which is suitable for administration in humans; and(b) is in a form in which (i) component (1) is in an effective dosage amount to treat said disease or condition by penetration at the site to be treated; and (ii) component (2) is immediately available to transport component (1) at the site to be treated, and which component (2) is in an effective non-toxic amount to facilitate the transport of component (1) upon administration, through the tissue including scar tissue, at the site to be treated and through the cell membranes or the individual cells to be